
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Сен. 3, 2024
Immunotherapy using inflammatory cytokines, such as interleukin (IL)-2 and interferon (IFN)-α, has been clinically validated in treating various cancers. However, systemic immunocytokine-based therapies are limited by the short half-life of recombinant proteins severe dose-limiting toxicities. In this study, we exploited local immunotherapy intratumoral administration lipid nanoparticle (LNP)-encapsulated mRNA cocktail encoding cytokines IL-12, IL-7, IFN-α. The cytokine induced tumor regression multiple syngeneic mouse models anti-tumor immune memory one model. Additionally, checkpoint blockade further enhanced efficacy mRNAs. Furthermore, human mRNAs exhibited robust humanized models. Mechanistically, microenvironment inflammation, characterized T cell infiltration significant chemokine production.
Язык: Английский